CAR Ts make the move to earlier lines of treatment despite access barriers

CAR T manufacturers and payers are still negotiating access for B cell lymphoma patients without other treatment options, but that hasn’t stopped companies from pressing on into earlier lines of treatment.

With evidence of durability mounting and strategies to mitigate toxicity bringing down the safety risks, CAR T developers are mapping out strategies to reach more patients. One area where they’ve begun to break ground is moving the new modality earlier in the course of treatment. ...